![Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016](https://img.yumpu.com/55798391/1/500x640/hereditary-angioedema-hae-c1-esterase-inhibitor-c1-inh-deficiency-pipeline-review-h1-2016.jpg)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016
‘Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016’, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
‘Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016’, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Hereditary</strong> <strong>Angioedema</strong> (<strong>HAE</strong>) (<strong>C1</strong> <strong>Esterase</strong> <strong>Inhibitor</strong><br />
[<strong>C1</strong>-<strong>INH</strong>] <strong>Deficiency</strong>) - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2016</strong><br />
TELEPHONE: +1 (503) 894-6022<br />
E-MAIL: sales@researchbeam.com
Report Overview<br />
The report provides comprehensive information on the therapeutics under development for<br />
<strong>Hereditary</strong> <strong>Angioedema</strong> (<strong>HAE</strong>) (<strong>C1</strong> <strong>Esterase</strong> <strong>Inhibitor</strong> [<strong>C1</strong>-<strong>INH</strong>] <strong>Deficiency</strong>), complete with<br />
analysis by stage of development, drug target, mechanism of action (MoA), route of<br />
administration (RoA) and molecule type. The report also covers the descriptive<br />
pharmacological action of the therapeutics, its complete research and development history<br />
and latest news and press releases. Additionally, the report provides an overview of key players<br />
involved in therapeutic development for <strong>Hereditary</strong> <strong>Angioedema</strong> (<strong>HAE</strong>) (<strong>C1</strong> <strong>Esterase</strong> <strong>Inhibitor</strong><br />
[<strong>C1</strong>-<strong>INH</strong>] <strong>Deficiency</strong>) and features dormant and discontinued projects.<br />
Report features investigational drugs from across globe covering over 20 therapy areas and<br />
nearly 3,000 indications. The report is built using data and information sourced from Global<br />
Markets Direct’s proprietary databases, company/university websites, clinical trial registries,<br />
conferences, SEC filings, investor presentations and featured press releases from<br />
company/university sites and industry-specific third party sources. Drug profiles featured in the<br />
report undergoes periodic review following a stringent set of processes to ensure that all the<br />
profiles are updated with the latest set of information. Additionally, various dynamic tracking<br />
processes ensure that the most recent developments are captured on a real time basis.<br />
<br />
Read More At: http://www.researchbeam.com/hereditary-angioedema-hae-c1-esterase-inhibitor-c1-inh-deficiencypipeline-review-h1-<strong>2016</strong>-market
Report Overview<br />
Scope<br />
-The report provides a snapshot of the global therapeutic landscape of <strong>Hereditary</strong> <strong>Angioedema</strong> (<strong>HAE</strong>) (<strong>C1</strong><br />
<strong>Esterase</strong> <strong>Inhibitor</strong> [<strong>C1</strong>-<strong>INH</strong>] <strong>Deficiency</strong>)<br />
- The report summarizes all the dormant and discontinued pipeline projects<br />
- The report reviews latest news related to pipeline therapeutics for <strong>Hereditary</strong> <strong>Angioedema</strong> (<strong>HAE</strong>) (<strong>C1</strong><br />
<strong>Esterase</strong> <strong>Inhibitor</strong> [<strong>C1</strong>-<strong>INH</strong>] <strong>Deficiency</strong>)<br />
Reasons to buy<br />
- Identify and understand important and diverse types of therapeutics under development for <strong>Hereditary</strong><br />
<strong>Angioedema</strong> (<strong>HAE</strong>) (<strong>C1</strong> <strong>Esterase</strong> <strong>Inhibitor</strong> [<strong>C1</strong>-<strong>INH</strong>] <strong>Deficiency</strong>)<br />
- Identify potential new clients or partners in the target demographic<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline<br />
therapeutics<br />
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that<br />
drove them from pipeline<br />
Read More At: http://www.researchbeam.com/hereditary-angioedema-hae-c1-esterase-inhibitor-c1-inh-deficiencypipeline-review-h1-<strong>2016</strong>-market
Table Of Contents<br />
List of Figures<br />
Number of Products under Development for <strong>Hereditary</strong> <strong>Angioedema</strong> (<strong>HAE</strong>) (<strong>C1</strong> <strong>Esterase</strong> <strong>Inhibitor</strong> [<strong>C1</strong>-<br />
<strong>INH</strong>] <strong>Deficiency</strong>), <strong>H1</strong> <strong>2016</strong> 10<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2016</strong> 11<br />
Comparative Analysis by Clinical Stage Development, <strong>H1</strong> <strong>2016</strong> 13<br />
Comparative Analysis by Early Stage Products, <strong>H1</strong> <strong>2016</strong> 14<br />
Assessment by Monotherapy Products, <strong>H1</strong> <strong>2016</strong> 29<br />
Number of Products by Targets, <strong>H1</strong> <strong>2016</strong> 30<br />
Number of Products by Stage and Targets, <strong>H1</strong> <strong>2016</strong> 30<br />
Number of Products by Mechanism of Actions, <strong>H1</strong> <strong>2016</strong> 32<br />
Number of Products by Stage and Mechanism of Actions, <strong>H1</strong> <strong>2016</strong> 32<br />
Number of Products by Routes of Administration, <strong>H1</strong> <strong>2016</strong> 34<br />
Number of Products by Stage and Routes of Administration, <strong>H1</strong> <strong>2016</strong> 34<br />
Number of Products by Molecule Types, <strong>H1</strong> <strong>2016</strong> 36<br />
Number of Products by Stage and Molecule Types, <strong>H1</strong> <strong>2016</strong> 36<br />
Read More At: http://www.researchbeam.com/hereditary-angioedema-hae-c1-esterase-inhibitor-c1-inh-deficiencypipeline-review-h1-<strong>2016</strong>-market
FOR MORE DETAILS<br />
Visit us at<br />
http://www.researchbeam.com/hereditary-angioedema-hae-c1-<br />
esterase-inhibitor-c1-inh-deficiency-pipeline-review-h1-<strong>2016</strong>-market<br />
Stay With Us<br />
TELEPHONE: +1 (800) 910-6452<br />
DIRECT: +1 (503) 894-6022<br />
E-MAIL: sales@researchbeam.com<br />
5933 NE Win Sivers Drive,<br />
#205, Portland, OR 97220<br />
United States
Change language